Research ArticleArticle
Adiposity in Juvenile Psoriatic Arthritis
Aaida Samad, Matthew L. Stoll, Idit Lavi, Joyce J. Hsu, Vibeke Strand, Thomas N. Robinson, Elizabeth D. Mellins, Devy Zisman and
for the CARRA Legacy Registry Investigators
The Journal of Rheumatology December 2017, jrheum.170598; DOI: https://doi.org/10.3899/jrheum.170598
Aaida Samad
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Matthew L. Stoll
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Idit Lavi
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Joyce J. Hsu
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Vibeke Strand
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Thomas N. Robinson
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Elizabeth D. Mellins
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Devy Zisman
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
From the School of Medicine, Case Western Reserve University, Cleveland, Ohio; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine and Department of Pediatrics, and divisions of Allergy, Immunology and Rheumatology, and Human Gene Therapy, and General Pediatrics, Stanford University, Palo Alto, California, USA; Department of Rheumatology and the Department of Community Medicine and Epidemiology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), the Arthritis Foundation Great Western Region Center of Excellence for Arthritis (to EDM), and the Rheumatology Research Foundation (to AS and EDM). The CARRA registry is supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; RC2AR058934), Friends of CARRA, and the Arthritis Foundation, as well as by the Duke Clinical Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAMS or the US National Institutes of Health. A. Samad, BA, Case Western Reserve University School of Medicine; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; V. Strand, MD, MACR, FACP, Department of Medicine, Division of Immunology and Rheumatology; T.N. Robinson, MD, Departments of Pediatrics and Medicine, Division of General Pediatrics; E.D. Mellins, MD, Department of Pediatrics, divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University; D. Zisman, MD, Department of Rheumatology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion. Dr. Mellins and Dr. Zisman contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa, Israel. E-mail: devyzisman@gmail.com, devyzi@clalit.org.il. Accepted for publication September 26, 2017.
Abstract
Objective Adult patients with psoriatic arthritis are at increased risk for obesity and metabolic syndrome, but data regarding adiposity in children with juvenile psoriatic arthritis (JPsA) are limited. Our study assessed adiposity in children with JPsA in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.
Methods Patients with JPsA in the CARRA registry were divided into nonoverweight and overweight groups using recommendations from the US Centers for Disease Control, and differences in demographic and clinical characteristics between groups at baseline and after 1-year followup were assessed using chi-square test, Fisher’s exact test, T test, or Mann-Whitney U test, as appropriate. The prevalence of overweight status in the JPsA registry patients was compared to rheumatoid factor–positive and –negative polyarticular juvenile idiopathic arthritis (RF+polyJIA; RF–polyJIA) registry cohorts and the US pediatric population, using a chi-square goodness-of-fit test.
Results Overweight children represented 36.3% of this JPsA cohort (n = 320). Compared to nonoverweight children, they were significantly older at symptom onset and rheumatologist’s first assessment, and scored significantly worse on patient/physician outcome measures. At 1-year followup, changes in body mass index were not associated with changes in clinical features or outcome measures. The prevalence of overweight and obesity in patients with JPsA was significantly higher than in RF+polyJIA patients, RF–polyJIA patients, and the US pediatric population.
Conclusion In this registry, almost 1 in 5 patients with JPsA were obese and more than one-third were overweight. This is significantly more than expected compared to the US pediatric population, and appropriate longterm followup of this JPsA subgroup is warranted.
In this issue
The Journal of Rheumatology
Vol. 50, Issue 3
1 Mar 2023
Adiposity in Juvenile Psoriatic Arthritis
Aaida Samad, Matthew L. Stoll, Idit Lavi, Joyce J. Hsu, Vibeke Strand, Thomas N. Robinson, Elizabeth D. Mellins, Devy Zisman,
for the CARRA Legacy Registry Investigators
The Journal of Rheumatology Dec 2017, jrheum.170598; DOI: 10.3899/jrheum.170598
Adiposity in Juvenile Psoriatic Arthritis
Aaida Samad, Matthew L. Stoll, Idit Lavi, Joyce J. Hsu, Vibeke Strand, Thomas N. Robinson, Elizabeth D. Mellins, Devy Zisman,
for the CARRA Legacy Registry Investigators
The Journal of Rheumatology Dec 2017, jrheum.170598; DOI: 10.3899/jrheum.170598
